All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 2: Cardiovascular
Toggle Parent Pages
Print this page
Management of atrial fibrillation
Management of other arrhythmias
Drugs that prolong the QT interval
Anticoagulation prescribing guidance
Management of suspected deep vein thrombosis (DVT) and pulmonary embolism (PE)
Secondary prevention of stroke / TIA
Management of angina
Chronic heart failure guidance
Management of hypertension
Management of blood lipids
2.1 Positive inotropic drugs
2.2 Diuretics
2.3 Anti-arrhythmic drugs
2.4 Beta-adrenoceptor blocking drugs
2.5 Hypertension and heart failure
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
2.7 Sympathomimetics
2.8 Anticoagulants and protamine
2.9 Antiplatelet drugs
2.10 Stable angina, acute coronary syndromes, and fibrinolysis
2.11 Antifibrinolytic drugs and haemostatics
2.12 Lipid-regulating drugs
2.14 Miscellaneous cardiovascular preparations
Contact us about this page
2.6.4 Peripheral vasodilators and related drugs
First Line
Second Line
Specialist
Hospital Only
Naftidrofuryl
- Capsules 100mg (£8.17 = 100mg three times a day)
Indication
- Intermittent claudication in peripheral vascular disease
Dose
- 100mg – 200mg three times a day
Notes
- Naftidrofuryl may improve the symptoms of patients suffering moderate disease (claudication distance less than 500 metres) but it is not known if it has any effect on the outcome of the disease.
- The benefit from any therapy initiated for the symptoms of intermittent claudication should be assessed at 3 months.
- See NICE TA223 Treatment of intermittent claudication in people with peripheral arterial disease (May 2011)
- NICE TA223 does not recommend cilostazol, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease.
